Abstract Glycogenosis type II, a genetic muscle-wasting disorder, results in a spectrum of clinical phenotypes.
Introduction
Glycogenosis type II (GSDII; OMIM 232300) is a rare autosomal recessive myopathy caused by the deficiency of the lysosomal enzyme acid α-glucosidase (GAA), which is involved in glycogen metabolism [10, 14] . As a result, glycogen accumulates in lysosomes of several cell types, particularly in skeletal muscle fibres. The storage leads to a progressive disarrangement of tissue architecture and, consequently, to muscular atrophy and loss of function.
Diagnosis of GSDII is a two-step process, the first being the formulation of a clinical suspicion while the second the measurement of GAA activity in peripheral blood cells, cultured fibroblasts or muscle biopsies [7] . If GAA activity is absent or deficient, diagnosis is confirmed. The molecular analysis of the GAA gene is also recommended, particularly in patients whose clinical, morphologic and biochemical features are inconclusive [2, 7, 37] , and plays an important role in genetic counselling. Moreover, it could be useful to predict the development of antibodies to exogenous enzyme, thus identifying children at risk for a poor response to enzyme replacement therapy (ERT) [6] .
GSDII encompasses a broad spectrum of clinical phenotypes, according to age at onset, severity and organ involvement [7, 22] . Nevertheless, patients are usually classified as having the infantile (classic and non-classic forms) or the lateonset form (juvenile or adult). In the classical infantile disease, the main clinical features are cardiomyopathy and muscular hypotonia, rapidly leading to respiratory failure and death within the 1st year of life, if untreated [16, 21, 29] , while the non-classic infantile form is characterised by a slower progressive cardiac and pulmonary involvement that generally leads to death during later infancy and early childhood [7, 24] . In late-onset GSDII the rate of disease progression is slower, cardiomyopathy is usually absent, and the prevalent manifestations involve both skeletal and respiratory muscles, causing a progressive limb-girdle myopathy and a variable degree of respiratory impairment [12, 19, 36, 38] . Most of the untreated late-onset patients become wheelchair and ventilator dependent, and respiratory failure represents the leading cause of death [12, 13, 36] .
Until the late 1990s, no specific therapies were available for patients affected by GSDII, other than supportive care [23] . In 2006, ERT using recombinant human GAA was introduced and approved for all GSDII patients, on the basis of open-label studies showing improvements in survival, cardiac function and motor outcomes in the classic infantile form [1, 15, 17, 30, 31] . So far, studies on the effectiveness of ERT in late-onset phenotypes [3, 8, 25, 27, 28, 33, 34] demonstrate positive but variable long-term effects. The late-onset treatment study (LOTS) [34] and the observational studies published by Angelini [3] and Strothotte [25] provided evidence on ERT clinical effectiveness in improving functional exercise capacity and stabilising lung volumes over 18-, 12-and 36-month periods, respectively. However, much uncertainty still exists over the use of ERT in the paediatric clinical practice. In particular, the long-term effects on juvenile GSDII were not much studied so far [8, 28] , and the correct timing for treatment start is still controversial. Focusing on juvenile GSDII patients, the purpose of this retrospective cohort study was to critically evaluate the long-term effects of ERT on muscle enzymes levels, motor performance and respiratory function over a long-term intravenous treatment (up to 7 years of follow-up).
Patients and methods
A retrospective cohort study was conducted in 2013 on a group of eight Italian juvenile GSDII patients receiving biweekly infusions of 20 mg/kg recombinant human α-glucosidase and followed-up at the Regional Coordinator Centre for Rare Diseases, University Hospital "Santa Maria della Misericordia", Udine. The study was approved by the local ethics committee, and patients were enrolled after informed consent was obtained from them or their parents.
To be included in the study, patients needed to have a confirmed diagnosis of GSDII, defined as presenting with deficient GAA enzyme activity and/or GAA gene pathogenic mutations. GAA activity was measured in lymphocytes, cultured skin fibroblasts or muscle biopsies and was reported as a percentage of the activity recorded in healthy controls.
A trained paediatrician reviewed all clinical documentations and gathered data on pretreatment demographic and clinical history (age at onset, age and disease duration at first infusion, use of ambulation devices, need for respiratory support). Information on height, weight, muscle enzymes [creatine phosphokinase (CK), lactate dehydrogenase (LDH), alanine transaminase (ALT), aspartate transaminase (AST)], sixminute walk test (6MWT), forced vital capacity (FVC) and global motor disability during follow-up was collected as well. All parameters were evaluated at baseline (T0) and annually afterwards. Body mass index (BMI) was calculated with the standard formula [Weight (in kilogrammes)]/[Height (in metres)×Height (in metres)], and the corresponding Z scores were computed using age-and gender-specific paediatric reference values [18] . Six-minute walk test was performed according to the American Thoracic Society guidelines [4] . Patients rated their dyspnoea and overall fatigue at baseline and at the end of the exercise using the Borg scale [9] . The maximum distance walked was recorded in metres, while Z scores were computed using paediatric age-and genderspecific reference values [11] . Pulmonary function tests were performed in the upright position, according to current guidelines [20] . Forced vital capacity was expressed as a percentage of the predicted value (FVC); the maximum value of three reproducible measurements was used for analysis. Global motor disability was assessed through the modified Walton scale (WS; from 0=normal to 7=wheelchair bound) [23, 35] . Data were analysed, and graphics were plotted using the statistical package Stata (Stata Statistical Software: Release 11.0, 2009. StataCorp LP, College Station, TX, USA).
Results
Eight unrelated juvenile GSDII patients (five males and three females, born between 1991 and 1999) were enrolled in March 2013. Seven of them were already included in a study on late-onset GSDII published in 2010 [8] . Their characteristics at baseline (therapy start) are reported in Tables 1 and 2 .
In six patients, the first sign of disease was a CK increase, incidentally observed when a blood test was performed for different reasons (e.g. after detection of increased AST and ALT during a gastroenteritis), while the clinical onset was characterised by walking abnormalities for patient (Pt) 2 and by difficulty in climbing stairs for Pt 3. In all patients, the diagnosis was made within 1 year from clinical onset.
The GAA enzyme activity at diagnosis ranged between 3 and 10.6 % of normal values. All patients showed the splicing mutation c-32-13 T>G on one allele; different mutations were found in the second allele in five patients, while the second mutation remained unknown in three. However, in two of them, GAA mRNA analysis showed that the second allele was not expressed, suggesting that the unknown allele may harbour an unidentified mutation in the non-coding regions of the GAA gene that prevent the formation of a stable mRNA.
Most patients (n=6) started being treated shortly after the availability of ERT as a treatment for all GSDII forms, while two (Pts 6 and 7) started therapy after a couple of years. Overall, the age at therapy start ranged from 7.2 to 15 years. At therapy start, all patients showed a pathological elevation of CK (median 914 UI/L; range 366-1305), LDH (median 813 UI/L; range 520-1,561), ALT (median 120 UI/L; range 83-322) and AST (median 132 UI/L; range 79-283).
Six patients did not show a significant muscle function impairment at baseline (WS scores of ≤2), while two (Pts 2 and 4) showed worse WS scores (2.5 and 7, respectively), one of them (Pt 2) already being wheelchair bound. The performance at 6MWT was variable, with a Z score ranging between −11.41 and 0.28. Finally, three patients had a decreased pulmonary function (restrictive spirometry pattern). Among them, patients 2 and 4 showed a severe impairment (FVC of <40 % predicted) and already required a ventilatory support.
Data on a 6-year follow-up were available for all patients except one (Pt 6), who started therapy at the end of 2008 and whose length of follow-up was 4 years. This patient developed a brain tumour (pinealoblastoma) in 2012, and his follow-up visit was delayed due to surgery and hospitalisation. Patients 2 and 3 have been followed-up for 7 years. One patient developed an allergic reaction (skin rash) following the second infusion. This led him to be pretreated with intravenous antihistamine drugs before the following infusions, without further problems. No adverse effects were reported in all the other patients throughout the entire follow-up period. During the follow-up, muscle enzymes showed a sharp decrease after 1-2 years from therapy start and a stabilisation afterwards (Fig. 1) . However, CK levels decreased to normal values (expressed as inferior to 170 UI/L) only in one patient (Pt 7).
Global motor disability (modified Walton scale) remained unchanged in all patients.
When the performance at 6MWT was examined, two groups (Pts 2 and 4 vs others) were identified, according to disease severity. A slight improvement was clear in both, irrespective of their performance at therapy start (Fig. 2) , although only in three patients that Z scores were normal at the end of follow-up. When the respiratory and muscular fatigue experienced after the test was analysed (Borg scale), an improvement was observed at T5 (5 years after ERT start) in five patients ( Table 2) .
The same two groups could be identified when the FVC was studied as well. In both, a similar trend was seen, patients being quite stable in time, irrespective of their baseline pulmonary function (Table 2, Fig. 3 ). However, in Pts 2 and 4, a gradual reduction of ventilatory support was possible after therapy start. This led Pt 4 to stop non-invasive ventilation after 2 years, although starting it again 4 years later due to a moderate hypercapnia (pCO 2 52 mmHg). Finally, BMI Z score remained negative or decreased to negative values in most patients (six out of eight) (Fig. 4) .
Discussion
It is well known that ERT is effective in infants with GSDII [1, 15, 17, 30, 31] , while experience in late-onset disease is still limited, particularly in juvenile patients [8, 28] . However, due to the differences in the clinical manifestation of these forms, a diversified investigation seems to be worthwhile.
This retrospective cohort study aimed to describe the longterm effects of ERT in eight Italian juvenile GSDII patients, starting therapy during childhood and being treated for at least 72 months.
Although most patients did not show muscle function impairment before therapy start, muscle enzymes were pathologically high in all of them, and the introduction of ERT resulted in an initial decrease and a subsequent stabilisation. This trend is consistent with previously published studies [8, 25] . Moreover, the improvement in CK concentrations as an effect of ERT is important, in the light of the possible role of CK as a sensitive marker of muscle damage [5] .
Performances at 6MWT, variable at therapy start, slightly improved in seven out of eight patients during the follow-up. In fact, patients were able to walk longer distances, and in several cases, the respiratory and muscular fatigue after the test was milder, irrespective of the distance walked. A strength worth to be mentioned is that the metres walked at the 6MWT were normalised for age and gender. This adjustment is particularly important when children are investigated in a longitudinal fashion, since it allows a comparison with peers of the same age and gender, in order to prevent misinterpreting stability or increase in the metres walked as stabilisation or improvement, when it could even represent worsening. The pulmonary function remained quite stable in time in all the patients, whether they were impaired at baseline or not. This apparent absence of effect should be read in the light of the results of previous studies on late-onset untreated patients, describing a worsening in lung function and exercise tolerance [32, 38] and, especially, a loss of predicted FVC, ranging between 1.6 % per year [32] and 2.2 % in 18 months [34] . Moreover, our results are consistent with the improvement of functional exercise capacity and stabilisation of lung volumes already described in previous studies [3, 8, 25] . However, Van der Ploeg et al. suggested that the effect on both motor and pulmonary functions is larger in patients with higher residual muscular function at baseline, while in our patients, a similar trend is observed in all, irrespective of their baseline performance [34] . This may be explained by the difference between the two study groups, since Van der Ploeg described a cohort mainly represented by late-onset GSDII patients, mostly starting ERT over the third decade of life, while our patients received an early treatment during childhood and had, therefore, a shorter disease length.
The BMI trends during the follow-up were variable at the individual level, but an overall decrease could be observed, to be ascribed either to a weight loss or to a weight gain not appropriate for height. However, BMI-although adjusted for age and gender-does not allow to distinguish whether the muscle or fat tissues were lost; thus, opposite explanations can be suggested. First, patients with a better muscle function could practice more physical activity and, consequently, lose fat. On the other hand, patients finding exercise too tiring could practice less and, consequently, lose muscle. Therefore, it would be useful to evaluate body composition in GSDII patients, in order to understand the underlying mechanism of this decrease. In this study, unfortunately, body composition (as measured by dual X-ray absorbimetry total body scan) was not systematically assessed.
In this paper, we describe five patients who started treatment during childhood, despite being asymptomatic. Interestingly, none of them developed muscle or respiratory symptoms after 6 years of follow-up, all showed a decrease in muscle enzymes, and one normalised. These data suggest that early ERT initiation may prevent or, at least, delay the onset of GSDII symptoms. However, we do not know how the natural history of these patients would have been, in the absence of treatment. Treating these patients before the clinical onset is not a widespread therapeutic decision, and the optimal timing for therapy start in juvenile GSDII patients is still a debated issue. However, since ERT seems to be more successful when administered prior to irreversible muscle damage [34] , it is reasonable to consider that ERT should be started before the frank clinical onset of the disease. In fact, ERT seems to be more efficient on preserved than on damaged muscle, as suggested by the characterisation of pre-and post-ERT histopathology in infantile forms, provided by Thurberg et al. [26] . In their research, some features, such as low glycogen levels, mild ultrastructural damage, high proportion of type I fibres and young age at ERT start, were associated with a good histological response to ERT. Therefore, an early treatment could allow young patients to have a slower deterioration in their muscular function. However, the correct timing for therapy start in juvenile GSDII patients is still controversial, since no randomised controlled trials were performed on this subject, and only small observational retrospective studies are available in the literature, preventing from drawing strong conclusions. Our study itself suffers from these limitations, analysing data from only eight heterogeneous patients in a retrospective fashion. Therefore, there is the crucial need for appropriately conducted research able to compare the effectiveness of different timings for ERT start. These studies should be experimental, multi-centric and sufficiently large to achieve the power to detect clinically relevant differences.
In conclusion, our results suggest that ERT is effective in stabilising both motor and lung functions in juvenile patients with GSDII. However, well-conducted randomised controlled trials are necessary to understand whether an early treatment allows juvenile patients to reach adulthood with a more beneficial residual muscular function than untreated patients.
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